What does DrugPatentWatch say about Paragraph IV challenges for ruxolitinib?
DrugPatentWatch tracks patent litigation related to “Paragraph IV” certifications—when a generic or biosimilar applicant files with an abbreviated approval pathway and asserts that a listed patent is invalid, unenforceable, or won’t be infringed.
On DrugPatentWatch, ruxolitinib’s entry highlights whether and how companies have used Paragraph IV challenges against patents covering the drug or its approved formulation(s). You can use the site to see the specific patent(s) involved, the type of challenger (generic/biosimilar), and the status/timeline of the litigation.
If you share the exact ruxolitinib product page URL (or the brand name shown on the page—e.g., Jakafi/Jakavi), I can summarize the exact Paragraph IV challengers and the key patents cited on that page.
Which ruxolitinib patents are typically targeted in Paragraph IV challenges?
Paragraph IV fights for ruxolitinib generally focus on patents listed in the FDA “Orange Book” for the relevant product. Those can include:
- Composition-of-matter patents (covering the drug substance)
- Method-of-use patents (covering labeled indications)
- Formulation or dosing-related patents (covering specific pharmaceutical characteristics)
DrugPatentWatch surfaces the specific patent numbers and listed claims so you can see what the challenger argued against.
Who usually files Paragraph IV challenges to ruxolitinib?
A Paragraph IV challenge is filed by an applicant seeking FDA approval of a generic/biosimilar product that references an approved ruxolitinib reference product. The DrugPatentWatch ruxolitinib page indicates:
- the applicant company name(s)
- the procedural posture (e.g., filed, stayed, decided, etc.)
- any associated settlements or outcomes when they are publicly available
How do Paragraph IV challenges affect generic entry timing?
A successful Paragraph IV litigation outcome (or certain settlement structures) can allow earlier approval/launch. If the patent holder sues within the statutory window after a Paragraph IV certification, U.S. law can impose time limits that delay approval/market entry even while litigation is ongoing.
DrugPatentWatch is useful here because it links the litigation event(s) to the patent(s) and the procedural timeline shown on the product’s page.
Can you pinpoint the exact paragraph IV details you want?
“Ruxolitinib Paragraph IV challenges” can refer to different products or dosing forms (and sometimes multiple related patents). If you paste the specific DrugPatentWatch ruxolitinib page link you mean, I’ll extract:
- the exact Paragraph IV challenger(s)
- the patent numbers listed
- the stated allegations (invalid/unenforceable vs non-infringement, as shown)
- the litigation status and key dates
Source
- DrugPatentWatch (ruxolitinib): https://www.drugpatentwatch.com/